

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): November 11, 2005

Arrhythmia Research Technology, Inc.

(Exact name of issuer as specified in its charter)

Delaware
*(State or other jurisdiction of
Incorporation or organization)*

1-9731
(Commission File Number)

72-0925679
(I.R.S. Employer Identification Number)

25 Sawyer Passway
Fitchburg, MA 01420
(Address of principal executive offices and zip code)

(978) 345-5000
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02. Results of Operations and Financial Condition

On November 11, 2005, The Company issued a press release announcing its financial results for the 3rd quarter ended September 30, 2005. The press release is attached as Exhibit 99.1 to this report.

The information set forth in the above Item 2.02 and the attached Exhibit 99.1 is furnished to, but shall not be deemed “filed” with the Commission for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise incorporated by reference into any filing pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such a filing.

Item 9.01. Financial Statements and Exhibits

(c). Exhibits

<u>Exhibit Number</u>	<u>Description</u>
99.1	Press Release dated November 11, 2005 announcing its financial results for the 3 rd quarter ended September 30, 2005.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Fitchburg, Commonwealth of Massachusetts, on the 15th day of November 2005.

ARRHYTHMIA RESEARCH TECHNOLOGY, INC.

By: /s/ David A. Garrison
David A. Garrison
Executive Vice President and
Chief Financial Officer

Exhibit Index

<u>Exhibit Number</u>	<u>Description</u>
99.1	Press Release dated November 11, 2005 announcing its financial results for the 3 rd quarter ended September 30, 2005.



ARRHYTHMIA RESEARCH TECHNOLOGY, INC.

25 Sawyer Passway, Fitchburg, MA 01420 · Phone: 978-345-0181 · Fax: 978-342-0168 · www.arthrt.com

FOR IMMEDIATE RELEASE

Website: <http://www.arthrt.com>

Contact: David A. Garrison

(978) 345-5000

November 11, 2005

**ARRHYTHMIA RESEARCH TECHNOLOGY, INC.
ANNOUNCES RESULTS FOR THIRD QUARTER 2005**

Fitchburg, MA

Arrhythmia Research Technology, Inc. (the “Company”) (AMEX: HRT) and its wholly owned subsidiary Micron Products, Inc. (“Micron”) reported total revenue of \$3,339,000 and net income of \$263,000 for the quarter ended September 30, 2005 compared to total revenue of \$2,981,000 and net income of \$439,000 for the same quarter of 2004. Diluted net income per share for the three months ended September 30, 2005 was \$0.10 per share as compared to \$0.16 per share the same period in 2004.

For the nine months ended September 30, 2005, the Company achieved total revenue of \$9,871,000 and net income of \$1,137,000 as compared to total revenue of \$8,247,000 and net income of \$1,198,000 for the same period in 2004. Diluted net income per share for the nine months ended September 30, 2005 was \$0.42 as compared to \$0.45 for the same period in 2004.

James E. Rouse, the Company’s President and CEO commented, “Sales revenues increased 12% in the third quarter as compared with the same period last year resulting in overall revenue growth of 19.7% for the first nine months of 2005 compared with the first nine months of 2004. However, the rising cost of raw materials and energy along with an increase in low margin tool sales resulted in a greater than 5% drop in gross profit in the third quarter compared with the same period in 2004. This decrease in gross profit percentage along with one time \$190,000 cost associated with the administrative restructuring of the New England Molders division and an unexpected 50% increase in our outside audit fees, similar to other company’s experience, resulted in a decrease in quarter over quarter net income and EPS. Our tooling sales have a much lower margin when compared to product sales. We are confident that the increased tooling revenue is an indication of future production revenue as the tools are qualified and begin producing new products with higher margins. Also, we are optimistic that the strengthening of our sales and business development assets that has taken place so far in 2005 will produce additional sales revenue of existing products and new business in the future.”

The Company, through Micron, manufactures silver plated and non-silver plated conductive resin sensors and distributes metal snaps used in the manufacture of disposable ECG, EEG, EMS, and TENS electrodes. Micron’s NEM division manufactures custom injection molded products for medical, electronic, industrial and consumer applications. The Company’s products also include proprietary signal-averaging electrocardiography (SAECG) software used in the detection of potentially lethal heart arrhythmias.

Forward-looking statements made herein are based on current expectations of the Company that involve a number of risks and uncertainties and should not be considered as guarantees of future performance. The factors that could cause actual results to differ materially include: interruptions or cancellation of existing contracts, impact of competitive products and pricing, product demand and market acceptance, risks, the presence of competitors with greater financial resources than the Company, product development and commercialization risks, and changing economic conditions in developing countries. More information about factors that potentially could affect the Company's financial results is included in the Company's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-KSB for the year ended December 31, 2004.